HK2 and colorectal carcinoma: Tunicamycin C can potentially reduce CRC progression through several mechanisms by targeting hexokinases (HK1, HK2), and hence, glycolytic pathways are disrupted, therefore reducing the energy supply to cancer cells, since cancer cells often rely on aerobic glycolysis (the Warburg effect) for energy [53,54].